Sinopharm: The first subject for multiple doses in Phase I/II clinical trial of VUM02 injection entered the group.

Zhongyuan Xiehe announced that its wholly-owned subsidiary, Wuhan Guanggu Zhongyuan Pharmaceuticals Co., Ltd.'s VUM02 injection is undergoing Phase I/II clinical trials for the treatment of grade II to IV acute graft-versus-host disease (GVHD) that has failed hormone therapy. The first subject in the phase I trial received multiple doses on July 17, 2026. As of May 2026, a total of 8.309 million yuan has been invested in the project. The drug must complete clinical trials, apply for marketing approval, and receive evaluation and approval before it can be marketed, with uncertainties.